Clinical Trials Logo

Filter by:
NCT ID: NCT03062098 Withdrawn - Clinical trials for Fertilization in Vitro

Optimizing the Technique of Embryo Transfer in IVF Using Better Imaging Guidance

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

This trial seeks to improve ultrasound imaging during embryo transfer in IVF by using a small, high resolution ultrasound probe used routinely for cardiac imaging in children.

NCT ID: NCT03061669 Recruiting - Heart Failure Clinical Trials

Respiratory Monitoring During Right Heart

Start date: February 26, 2017
Phase:
Study type: Observational

Respiratory monitoring during right heart catheterization to differentiate between various types of pulmonary hypertension; The effects of the cardiovascular system on the lung mechanical properties.

NCT ID: NCT03061552 Completed - Clinical trials for End Stage Renal Disease

Inferior Vena Cava Sonography in Hemodialysis Patients and Quality of Life

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Determination of dry weight in patients with end-stage renal disease treated with hemodialysis is an unmet challenge in clinical nephrology. Current methods are imprecise, and thus many patients are hype- or hypovolemic, and suffer respective consequences such as hypertension, pulmonary congestion, cardiac hypertrophy, chronic dehydration, hypotension and shock. Several techniques have been proposed to asses hydration status in dialysis patient, among them measurement of bioimpedance and biochemical markers. Sonographic measurement of the inferior vena cava diameter (IVCD) is a method under investigation for assessing hydration status. It is available, inexpensive and efficient, yet operator-dependent. In a single-center, blinded and controlled trial it has been shown to improve clinical outcomes in patients receiving hemodialysis. In this study, we aim to assess the applicability and clinical utility of this method in our dialysis units. A crossover design is intended to examine the effect of IVCD measurement on quality of life and rate of hemodynamic adversities as compared with traditional estimation of dry weight.

NCT ID: NCT03059706 Recruiting - Meniscal Tear Clinical Trials

The Effect of Intra-Articular Injection of RegenoGel-OSP™(Self-Plasma) to Treat Pain Following Arthroscopic Surgery

Start date: March 23, 2017
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of intra-articular administration of RegenoGel-OSP™ to treat pain and the safety and efficacy on subject's activity and quality of life following arthroscopic surgery due to degenerative or traumatic meniscal tear. adult subjects will be randomized and sequentially assigned to RegenoGel-OSP™ or placebo treatment on a 1:1 basis.

NCT ID: NCT03059615 Withdrawn - Clinical trials for Myelodysplastic Syndromes

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Start date: October 25, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, Open-label, one arm study in which the eligible patients will be treated with IV Nerofe, three times a week in 28 days cycles (up to 12 cycles). Evaluation will include safety procedures, blood level of study drug in certain time points, immune system response and tests checking the mechanism of the drug action.

NCT ID: NCT03057392 Completed - Clinical trials for Intradialytic Hypotension

Head Out Water Immersion for Hemodynamic Stability During Dialysis

Start date: May 2013
Phase: N/A
Study type: Interventional

Immersion to the neck before and during hemodialysis session may increase intravascular volume, potentiate the ability to ultrafiltrate excess water, with less symptoms of shock, muscle crumps etc. The aim of the present study is to compare blood volume, hemodynamic and endocrine parameters of chronic ESRD patients undergoing forth dialysis session in water immersion vs. control regular session.

NCT ID: NCT03057314 Terminated - Clinical trials for Solid Malignancies, With or Without Lung Metastases

Improving Function,Welfare of Late-stage Cancer Subjects by ACC

Start date: June 25, 2017
Phase: Phase 1
Study type: Interventional

To improve the function and welfare of late stage solid cancer subjects by: - enabling subjects to benefit from a potentially promising drug under development - assessing initial evidence of improvement in Pain VAS score - assessing initial improvement in Performance Status (PS) - assessing initial improvement in oxygen saturation whenever it is feasible

NCT ID: NCT03056755 Active, not recruiting - Breast Cancer Clinical Trials

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

BYLieve
Start date: August 14, 2017
Phase: Phase 2
Study type: Interventional

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), harboring PIK3CA mutations, who have progressed on or after prior treatments.

NCT ID: NCT03056066 Enrolling by invitation - Pulmonary Fibrosis Clinical Trials

Accuracy of Spircare Device as Compared to the Conventional Plethysmograph

Start date: July 31, 2017
Phase:
Study type: Observational

The purpose of this study is to assess the accuracy of FRC and airway resistance calculate values of Spircare device as compared to the conventional body plethysmograph in healthy adults and patients with obstructive and restrictive pulmonary diseases/disorders.

NCT ID: NCT03055013 Active, not recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

PROSPER
Start date: April 28, 2017
Phase: Phase 3
Study type: Interventional

This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent the cancer from returning. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.